Skip to content
StockMarketAgent
Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

BST/R2WA stock hub

BST/R2WA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

BST/R2WAis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
376M
Stuttgart Stock Exchange
Market data

Live price

Current market quote for this ticker.

Current price
BST/R2WA
In the news

Latest news · BST/R2WA

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E8.8
P25 n/aP50 n/aP75 n/a
Trailing P/E7.3
P25 n/aP50 n/aP75 n/a
ROE12.5
P25 n/aP50 n/aP75 n/a
ROIC12
P25 n/aP50 n/aP75 n/a
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All BST/R2WA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
209
Groups with data
11
Currency
BDT
Showing 209 of 209 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

18
MetricValue
Country
Bangladesh
Country code
DE
Employees
1,122
Employees Change
112%
Employees Change Percent
11.09
Enterprise value
EUR 426.5M
Exchange
Stuttgart Stock Exchange
Financial currency
BDT
First seen
2026-05-10
Industry
Pharmaceutical Preparations
Last refreshed
2026-05-10
Market cap
EUR 376M
Price
EUR 0.48
Price currency
EUR
Rev Per Employee
333,144.97x
Sic
2834
Symbol
bst/R2WA
Website
https://www.beximcopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

14
MetricValue
Earnings Yield
13.63%
EV Earnings
8.32x
EV/EBIT
7x
EV/EBITDA
5.81x
EV/FCF
12.91x
EV/Sales
1.33x
FCF yield
8.78%
Forward P/E
8.85x
P/B ratio
0.87x
P/E ratio
7.34x
P/S ratio
1.01x
PE Ratio10 Y
13.86x
PE Ratio3 Y
11.82x
PE Ratio5 Y
12.9x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

24
MetricValue
EBIT Margin
18.99%
EBITDA Margin
22.67%
FCF margin
8.84%
Gross margin
44.42%
Gross Profit
EUR 166M
Gross Profit Growth
14.22%
Gross Profit Growth Q
13.88%
Gross Profit Growth3 Y
10.76%
Gross Profit Growth5 Y
12.96%
Net Income
EUR 51.2M
Net Income Growth
29.23%
Net Income Growth Q
27.65%
Net Income Growth3 Y
1.38%
Net Income Growth5 Y
14.34%
Pretax Margin
17.73%
Profit Margin
13.71%
Profit Per Employee
EUR 45,675
ROA
7.62
Roa5y
7.06
ROCE
14.13
ROE
12.45
Roe5y
11.97
ROIC
12.04
Roic5y
10.37

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

21
MetricValue
Cagr1y
20.02%
Cagr3y
2.51%
Cagr5y
-10.04%
Div CAGR3
1.71%
Div CAGR5
-2.34%
EPS Growth
29.23
EPS Growth Q
27.65
EPS Growth3 Y
1.38
EPS Growth5 Y
14.34
FCF Growth
-33.1%
FCF Growth3 Y
-0.72%
FCF Growth5 Y
33.52%
OCF Growth
-18.89%
OCF Growth Q
-41.02%
OCF Growth10 Y
10.43%
OCF Growth3 Y
-4.03%
OCF Growth5 Y
2.67%
Revenue Growth
11.26x
Revenue Growth Q
12.8x
Revenue Growth3 Y
13.06x
Revenue Growth5 Y
13.87x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

21
MetricValue
Asset Turnover
EUR 0.64
Assets
EUR 595.3M
Cash
EUR 23M
Current Assets
EUR 170.2M
Current Liabilities
EUR 79.8M
Debt
EUR 50M
Debt EBITDA
EUR 0.58
Debt Equity
EUR 0.12
Debt FCF
EUR 1.51
Equity
EUR 432.6M
Interest Coverage
8.48
Liabilities
EUR 162.7M
Long Term Assets
EUR 425M
Long Term Liabilities
EUR 83M
Net Cash
EUR -26.9M
Net Cash By Market Cap
EUR -7.17
Net Debt EBITDA
EUR 0.32
Net Debt Equity
EUR 0.06
Net Debt FCF
EUR 0.82
Tangible Book Value
EUR 357.2M
Tangible Book Value Per Share
EUR 0.8

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
2.13
Inventory Turnover
1.77
Net Working Capital
EUR 116.2M
Quick ratio
0.6
Working Capital
EUR 105.6M
Working Capital Turnover
EUR 0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

5
MetricValue
Dividend Growth Years
1%
Dividend per share
EUR 0
Dividend Years
8
Last Dividend
EUR 0.02
Payout Ratio
24.96%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

33
MetricValue
1Y total return
20%
200-day SMA
0.49
3Y total return
7.71%
50-day SMA
0.49
50-day SMA vs 200-day SMA
50over200
5Y total return
-41.08%
All Time High
1.37
All Time High Change
-64.96%
All Time High Date
2022-01-03
All Time Low
0.23
All Time Low Change
112.39%
All Time Low Date
2024-09-04
ATR
0.02
Ch YTD
7.14
High
0.48
High52
0.79
High52 Date
2026-01-15
High52ch
-39.24%
Low
0.48
Low52
0.37
Low52 Date
2025-07-07
Low52ch
29.73%
Ma50ch
-1.6%
Price vs 200-day SMA
-1.09%
RSI
50.43
RSI Monthly
49.64
RSI Weekly
48.91
Sharpe ratio
0.55x
Sortino ratio
1
Tr YTD
7.14
Tr1m
3.9%
Tr1w
2.13%
Tr3m
0.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

6
MetricValue
Operating Income
EUR 71M
Operating Income Growth
20.1
Operating Income Growth Q
12.34
Operating Income Growth3 Y
9.21
Operating Income Growth5 Y
11.42
Operating margin
18.99

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

3
MetricValue
Net Borrowing
-9,436,227.2
Shares Institutions
0.1%
Shares Qo Q
0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

58
MetricValue
Adjusted FCF
EUR 33M
Average Volume
3,875x
Bv Per Share
0.9
CAPEX
EUR -20.5M
Ch1m
3.9
Ch1w
2.13
Ch1y
20
Ch3m
0.84
Ch3y
-4
Ch5y
-50.52
Ch6m
3
Change
-2.44%
Change From Open
0.42
Close
0.49
Days Gap
-2.85
Depreciation Amortization
11,787,692.7
Earnings Date
2026-01-27
EBIT
EUR 71M
EBITDA
EUR 84.7M
EPS
EUR 0.11
F Score
7
FCF
EUR 33M
FCF EV Yield
7.74x
Financing CF
-23,806,000
Fiscal Year End
June
Founded
1,976
Goodwill
4,662,266.2
Graham Number
0.90154
Graham Upside
87.82
Income Tax
EUR 14.7M
Investing CF
-25,270,410
Is Primary Listing
0
Last Earnings Date
2026-01-27
Last Report Date
2024-12-31
Last Split Date
2020-11-23
Last Split Type
Forward
Lynch Fair Value
EUR 0.94
Lynch Upside
95.4
Ma150
0.48
Ma150ch
-0.25%
Ma20
0.47
Ma20ch
1.16%
Net CF
4,512,576
Open
0.48
P FCF Ratio
11.38
P OCF Ratio
7.03
Payment Date
2025-02-06
Position In Range
100
Ppne
301,991,520.2
Price Date
2026-05-08
Price EBITDA
EUR 4.44
Ptbv Ratio
1.05
Relative Volume
2.35x
Revenue
373,788,654x
Tax By Revenue
3.93x
Tax Rate
22.17%
Tr6m
3%
Z Score
3.32
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does BST/R2WA pay a dividend?

Capital-return profile for this ticker.

Performance

BST/R2WA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+20.0%
S&P 500 1Y: n/a
3Y total return
+7.7%
S&P 500 3Y: n/a
5Y total return
-41.1%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns BST/R2WA?

Insider, institutional, and short-interest positioning.

Institutional ownership
+0.1%
Share of float held by funds and institutions
Insider ownership
n/a
Stake held by company insiders. Higher generally signals alignment.
Short interest
n/a
Float sold short by bearish positioning
Y/Y dilution
n/a
Negative means the company is buying back shares.
Technical

BST/R2WA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
50.4
Neutral momentum band
Price vs 200-day MA
-1.1%
50/200-day relationship not available
Beta (5Y)
n/a
Sensitivity to the broader market
Sharpe ratio
0.55
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About BST/R2WA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bst/R2WA stock rating?

bst/R2WA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bst/R2WA analysis?

The full report lives at /stocks/bst/R2WA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bst/R2WA?

The latest report frames bst/R2WA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bst/R2WA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.